$6.76+0.01 (+0.15%)
At close: Nov 20, 2026, 4:00 PM ET· Nasdaq · USD
Avalo Therapeutics (AVTX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 100% below its peak, net margin −132642.4%.
The four lines that matter · FY21–FY25
Revenue ($K)▼86.6%
59.0
FY21→FY25CAGR −67.7%/yr
Net income ($K)▼122.8%
−78,259.0
FY21→FY25CAGR —
Free cash flow ($K)—
—
no FY25 valueCAGR —
Diluted EPS—
−5.84
no value for 4 of 5 yearsCAGR —
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)
-132642¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Net margin -132642.4% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.2435, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 59.0 | 59.0 | 441.0 | 1,924.0 | 18,051.0 | 5,398.0 | ▼86.6% | −67.7% |
Cost of revenue | — | 0.0 | −366.0 | 1,284.0 | 3,434.0 | 1,491.0 | — | — |
Gross profit | 59.0 | — | 807.0 | 640.0 | 14,617.0 | 3,907.0 | — | — |
Research & development | 65,777.0 | 50,084.0 | 52,078.0 | 13,784.0 | 31,308.0 | 59,835.0 | ▼3.8% | −4.3% |
Selling, general & admin | 29,839.0 | 22,900.0 | 17,241.0 | 10,300.0 | 20,711.0 | 24,658.0 | ▲32.8% | −1.8% |
Total operating expenses | 95,616.0 | 72,984.0 | 69,319.0 | 27,991.0 | 52,057.0 | 86,041.0 | ▲5.3% | −4.0% |
Operating incomefeeds ROC rank | −95,557.0 | −72,925.0 | −68,512.0 | −27,351.0 | −37,440.0 | −82,134.0 | ▼6.4% | — |
Other income, net | 7,071.0 | −5,169.0 | 33,497.0 | −4,179.0 | −4,190.0 | −2,411.0 | — | — |
Pretax income | −88,486.0 | −78,094.0 | −35,015.0 | −31,530.0 | −41,630.0 | −84,545.0 | ▼123.0% | — |
Income tax | 167.0 | 165.0 | 114.0 | 14.0 | 28.0 | −196.0 | ▲44.7% | +80.6% (22→25) |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −88,653.0 | −78,259.0 | −35,129.0 | −31,544.0 | −41,658.0 | −84,376.0 | ▼122.8% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | — | −5.84 | — | — | — | — | — | — |
Diluted shares (mn) | — | 13.40 | — | — | — | — | — | — |
| Margins | ||||||||
Gross margin80th pct in Healthcare | 100.0% | — | 183.0% | 33.3% | 81.0% | 72.4% | — | — |
Operating margin | −161961.0% | −123601.7% | −15535.6% | −1421.6% | −207.4% | −1521.6% | ▼108066.1pp | −122080.1pp |
Net margin0th pct in Healthcare | −150259.3% | −132642.4% | −7965.8% | −1639.5% | −230.8% | −1563.1% | ▼124676.6pp | −131079.3pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-23 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Avalo Therapeutics' revenue last fiscal year?
Avalo Therapeutics reported revenue of $59.0K in fiscal 2025, down 86.6% from fiscal 2024.
What was Avalo Therapeutics' net income?
Avalo Therapeutics reported net income of −$78,259.0K in fiscal 2025, a net margin of −132642.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

